Dinshaw K A, Agarwal J P, Ghosh-Laskar S, Gupta T, Shrivastava S K
Tata Memorial Hospital, Mumbai, Maharashtra, India.
Clin Oncol (R Coll Radiol). 2006 Jun;18(5):383-9. doi: 10.1016/j.clon.2006.02.009.
Head and neck squamous cell carcinoma (HNSCC) continues to be a leading cancer in developing countries. Definitive radiation therapy either primary or as postoperative adjuvant is offered to most patients. We aimed to identify prognostic and therapeutic factors that affect locoregional control and survival in patients undergoing radical radiotherapy for head and neck squamous cell cancers.
A retrospective analysis of 568 previously untreated patients with squamous head and neck cancers, who received radical radiotherapy between 1990 and 1996, using local control, locoregional control and disease-free survival (DFS) as outcome measures.
With a median follow-up of 18 months for living patients, the 5-year local control, locoregional control and DFS for all 568 patients were 53%, 45% and 41%, respectively, for all stages combined. The 5-year local control, locoregional control and DFS as per the American Joint Committee on Cancer stage grouping were 78%, 70% and 70%; 64%, 59% and 57%; 51%, 42% and 37%; and 40%, 27% and 22% from stages I to IV, respectively, with highly significant P values. Patients receiving higher doses (> or = 66 Gy) had a significantly better outcome compared with lower doses. The 5-year local control (59% vs 48%, P = 0.0015), locoregional control (47% vs 41%; P = 0.0043) and DFS (44% vs 37%; P = 0.0099) were significantly better in patients receiving > or = 66 Gy. Site of primary also affected outcome significantly, with oral cavity lesions faring badly.
Tumour stage remains the most important factor affecting outcome in radical radiotherapy of HNSCC. A definite dose-response relationship exists with higher total doses, leading to better local control, locoregional control and DFS in all stages. Site of primary affects outcome too, with laryngeal primaries doing well and oral cavity cancers faring the worst.
头颈部鳞状细胞癌(HNSCC)在发展中国家仍然是主要的癌症类型。大多数患者接受了根治性放射治疗,无论是作为初始治疗还是术后辅助治疗。我们旨在确定影响头颈部鳞状细胞癌根治性放疗患者局部区域控制和生存的预后及治疗因素。
对1990年至1996年间接受根治性放疗的568例未经治疗的头颈部鳞状细胞癌患者进行回顾性分析,以局部控制、局部区域控制和无病生存期(DFS)作为观察指标。
存活患者的中位随访时间为18个月,所有568例患者的5年局部控制率、局部区域控制率和DFS分别为53%、45%和41%,所有分期合并计算。根据美国癌症联合委员会分期分组,I至IV期的5年局部控制率、局部区域控制率和DFS分别为78%、70%和70%;64%、59%和57%;51%、42%和37%;以及40%、27%和22%,P值具有高度显著性。接受较高剂量(≥66 Gy)的患者与较低剂量患者相比,预后明显更好。接受≥66 Gy的患者5年局部控制率(59%对48%,P = 0.0015)、局部区域控制率(47%对41%;P = 0.0043)和DFS(44%对37%;P = 0.0099)明显更好。原发部位也显著影响预后,口腔病变患者预后较差。
肿瘤分期仍然是影响HNSCC根治性放疗预后的最重要因素。总剂量越高,存在明确的剂量反应关系,在所有分期中均能带来更好的局部控制、局部区域控制和DFS。原发部位也影响预后,喉原发灶患者预后良好,口腔癌患者预后最差。